Inventor · disambiguated record
John C. Williams
Also filed as: WILLIAMS JOHN · WILLIAMS JOHN C · WILLIAMS JOHN CHARLES · WILLIAMS JOHN V
29 granted patents·32 pending applications·319 citations·filing 1976–2025
96Inventor score
Files withHOPE CITY43WILLIAMS JOHN C5SEQUOIA PACIFIC RES COMPANY LL2XILIO DEV INC2BELL TELEPHONE LABOR INC1
Top patents by PatentIndex Score
61 records- 0196US10357571B2Development of masked therapeutic antibodies to limit off-target effectsHOPE CITY·Filed 2015·Granted Jul 23, 2019·18 cites·8 claims
- 0296US9574014B2Chimeric antigen receptor compositionsHOPE CITY·Filed 2016·Granted Feb 21, 2017·41 cites·20 claims
- 0396US8962804B2Meditopes and meditope-binding antibodies and uses thereofWILLIAMS JOHN C·Filed 2012·Granted Feb 24, 2015·96 cites·22 claims
- 0494US11690908B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2021·Granted Jul 4, 2023·3 cites·10 claims
- 0594US11116834B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2017·Granted Sep 14, 2021·10 cites·11 claims
- 0694US8895702B2Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodiesWILLIAMS JOHN C·Filed 2012·Granted Nov 25, 2014·27 cites·4 claims
- 0792US12161714B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2023·Granted Dec 10, 2024·1 cites·6 claims
- 0891US9193791B2Development of masked therapeutic antibodies to limit off-target effectsWILLIAMS JOHN C·Filed 2012·Granted Nov 24, 2015·11 cites·4 claims
- 0990US9669108B2Meditopes and meditope-binding antibodies and uses thereofHOPE CITY·Filed 2014·Granted Jun 6, 2017·9 cites·8 claims
- 1090US4076380AGraded index optical fiberBELL TELEPHONE LABOR INC·Filed 1976·Granted Feb 28, 1978·62 cites·5 claims
- 1186US8658774B2Meditopes and related meditope-monoclonal antibody delivery systems, synthesis and therapeutic uses thereofWILLIAMS JOHN C·Filed 2011·Granted Feb 25, 2014·12 cites·8 claims
- 1282US10689423B2CTLA4-binding protein peptide-linker masksHOPE CITY·Filed 2016·Granted Jun 23, 2020·2 cites·15 claims
- 1381US11311622B2Development of masked therapeutic antibodies to limit off-target effectsHOPE CITY·Filed 2019·Granted Apr 26, 2022·1 cites·5 claims
- 1481US9428553B2Meditopes and meditope-binding antibodies and uses thereofHOPE CITY·Filed 2013·Granted Aug 30, 2016·4 cites·15 claims
- 1579US10590205B2Chimeric antigen receptor compositionsHOPE CITY·Filed 2017·Granted Mar 17, 2020·2 cites·17 claims
- 1678US11246942B2Meditopes and meditope-binding antibodies and uses thereofHOPE CITY·Filed 2017·Granted Feb 15, 2022·1 cites·7 claims
- 1777US10414814B2Tumor-selective CTLA-4 antagonistsHOPE CITY·Filed 2015·Granted Sep 17, 2019·2 cites·5 claims
- 1876US2023085485A1Design and development of masked therapeutic antibodies to limit off-target effectsHOPE CITY·Filed 2022·Application pending·0 cites
- 1974US2023001003A1Meditopes and meditope-binding antibodies and uses thereofHOPE CITY·Filed 2021·Application pending·0 cites
- 2074US2024425584A1Mechanically interlocking complexesHOPE CITY·Filed 2024·Application pending·0 cites
- 2174US2025289889A1Activatable masked anti-ctla4 binding proteinsXILIO DEV INC·Filed 2025·Application pending·0 cites
- 2272US2025066418A1Cysteine peptide-enabled antibodiesHOPE CITY·Filed 2024·Application pending·0 cites
- 2372US2025011465A1Multi-specific ligand bindersHOPE CITY·Filed 2024·Application pending·0 cites
- 2471US2023391887A1Multivalent meditopes, meditope-binding antibodies and uses thereofHOPE CITY·Filed 2022·Application pending·0 cites
- 2570US12384845B2Activatable masked anti-CTLA4 binding proteinsXILIO DEV INC·Filed 2019·Granted Aug 12, 2025·0 cites·14 claims
- 2669US9096844B2Photocleavable linkerHOPE CITY·Filed 2013·Granted Aug 4, 2015·1 cites·19 claims
- 2766US2025367270A1Symmetry based viral antagonistsHOPE CITY·Filed 2023·Application pending·0 cites
- 2865US12060435B2Multi-specific ligand bindersHOPE CITY·Filed 2019·Granted Aug 13, 2024·0 cites·10 claims
- 2965US11279752B2Tumor-selective CTLA-4 antagonistsHOPE CITY·Filed 2019·Granted Mar 22, 2022·0 cites·10 claims
- 3063US11926652B2CTLA4-binding protein peptide-linker masksHOPE CITY·Filed 2020·Granted Mar 12, 2024·0 cites·20 claims
- 3162US2016152711A1Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodiesHOPE CITY·Filed 2014·Application pending·0 cites
- 3261US6881008B1Particle binding compositions and methods of making and using such compositionsSEQUOIA PACIFIC RES COMPANY LT·Filed 2004·Granted Apr 19, 2005·11 cites·43 claims
- 3361US2020277400A1Chimeric antigen receptor compositionsHOPE CITY·Filed 2020·Application pending·0 cites
- 3460US11186642B2Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodiesHOPE CITY·Filed 2017·Granted Nov 30, 2021·0 cites·9 claims
- 3559US2024400686A1Anti-cd3 antibodies and uses thereofHOPE CITY·Filed 2022·Application pending·0 cites
- 3659US2025353924A1Anti-cd84 antibodies and uses thereofHOPE CITY·Filed 2023·Application pending·0 cites
- 3758US2022089642A1Fc Receptor-ACE2 Conjugates and Use ThereofHOPE CITY·Filed 2021·Application pending·0 cites
- 3857US2025320291A1Compositions and uses of cd19 targeted chimeric antigen receptor modified immune cellsHOPE CITY·Filed 2021·Application pending·0 cites
- 3955US2023250157A1Antibodies for coronavirus and uses thereofCALIFORNIA INST OF TECHN·Filed 2022·Application pending·0 cites
- 4054US2024317873A1Anti-hvem antibodiesHOPE CITY·Filed 2022·Application pending·0 cites
- 4154US2020368364A1Cysteine peptide-enabled antibodiesHOPE CITY·Filed 2017·Application pending·0 cites
- 4254US2009170940A1Modified ethyl formate compositions and methods for soil fumigationHERNANDEZ LILIA·Filed 2007·Application pending·0 cites
- 4353US9260710B2Photocleavable linkerHOPE CITY·Filed 2015·Granted Feb 16, 2016·0 cites·20 claims
- 4453US2023340089A1Smc1a antibodies and uses thereofHOPE CITY·Filed 2021·Application pending·0 cites
- 4553US2023141575A1Multivalent chemokine receptor binding complexesHOPE CITY·Filed 2021·Application pending·0 cites
- 4652US2024228629A1Anti-domain iv egfr antibodies and uses thereofHOPE CITY·Filed 2022·Application pending·0 cites
- 4752US2010189727A1Masking Ligands For Reversible Inhibition Of Multivalent CompoundsTEGOPHARM CORP·Filed 2009·Application pending·0 cites
- 4851US7005005B2Soil bind and revegetation compositions and methods of making and using such compositionsSEQUOIA PACIFIC RES COMPANY LL·Filed 2003·Granted Feb 28, 2006·1 cites·37 claims
- 4951US2010034782A1Methods of Using Anti-Thymocyte Globulin and Related AgentsNAJAFIAN NADER·Filed 2007·Application pending·0 cites
- 5051US2025228894A2Truncated domain iv egfr and uses thereofHOPE CITY·Filed 2022·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when John C. Williams files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →